BridgeMD
A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder (RENEW-ALC-1)
EU CTIS ID: 2025-522313-38-00
What this study is testing
Period 1 Primary Objective To demonstrate that at least 1 dose level of brenipatide is superior to placebo for at least 1 of the dual primary endpoints Period 2 Primary Objective For brenipatide responders from Period 1: To evaluate the ability of brenipatide (pooled across doses) to maintain a general reduction in alcohol consumption endpoint
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Motivated to stop or cut down on drinking.
- Willing to take part in the whole study and go to all the needed visits
- Willing to do what the study asks, like giving yourself the medicine, keeping and using the medicine as told, writing in study diaries, and answering questions.
You likely can't join if
- Used or currently use illegal drugs or medicines that were not prescribed to you in the past 180 days. This does not include alcohol, nicotine, or caffeine.
- Had serious liver problems in the past, like bad liver scarring (fibrosis or cirrhosis) or liver disease caused by alcohol, based on past liver tests or scans (like ultrasound, CT, MRI, or special blood tests).
The study team makes the final eligibility decision.
Where it's taking place
- Japan
- China
- Taiwan
- United States
- Argentina
- United Kingdom
- Korea, Democratic People's Republic of
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Japan; China; Taiwan; United States; Argentina; United Kingdom and 1 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.